Adicet Bio (ACET) Projected to Post Earnings on Tuesday

Key Points

• Adicet Bio is set to release its Q2 2025 earnings on August 12, with analysts anticipating a loss of ($0.32) per share.
• The company's stock recently traded at $0.73 with a market cap of $60.05 million and a P/E ratio of -0.56.
• Analysts have various ratings for Adicet Bio, with most rating it a "Moderate Buy"** and a target price averaging $6.00.

Adicet Bio (NASDAQ:ACET - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.32) per share for the quarter.

Adicet Bio (NASDAQ:ACET - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.03. On average, analysts expect Adicet Bio to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Adicet Bio Stock Performance

Shares of NASDAQ ACET traded up $0.04 during midday trading on Tuesday, hitting $0.73. The company's stock had a trading volume of 38,311 shares, compared to its average volume of 619,001. The firm has a market cap of $60.05 million, a P/E ratio of -0.56 and a beta of 1.59. Adicet Bio has a 1-year low of $0.45 and a 1-year high of $1.64. The firm's fifty day moving average price is $0.71 and its 200-day moving average price is $0.75.

Hedge Funds Weigh In On Adicet Bio

A hedge fund recently raised its stake in Adicet Bio stock. Goldman Sachs Group Inc. grew its holdings in Adicet Bio, Inc. (NASDAQ:ACET - Free Report) by 1.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,816,556 shares of the company's stock after acquiring an additional 63,691 shares during the quarter. Goldman Sachs Group Inc. owned 4.61% of Adicet Bio worth $2,882,000 at the end of the most recent reporting period. 83.89% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Wall Street Zen started coverage on Adicet Bio in a research report on Friday, May 16th. They set a "hold" rating for the company. HC Wainwright raised shares of Adicet Bio to a "strong-buy" rating and set a $4.00 target price for the company in a research report on Wednesday, July 23rd. Two research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Adicet Bio has an average rating of "Moderate Buy" and an average price target of $6.00.

Adicet Bio Company Profile

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.